During the last session, Pasithea Therapeutics Corp (NASDAQ:KTTA)’s traded shares were 2.17 million, with the beta value of the company hitting 0.53. At the end of the trading day, the stock’s price was $0.96, reflecting an intraday loss of -15.04% or -$0.17. The 52-week high for the KTTA share is $7.69, that puts it down -701.04 from that peak though still a striking 5.21% gain since the share price plummeted to a 52-week low of $0.91. The company’s market capitalization is $2.84M, and the average trade volume was 5.59 million shares over the past three months.

Pasithea Therapeutics Corp (NASDAQ:KTTA) trade information

Pasithea Therapeutics Corp (KTTA) registered a -15.04% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -15.04% in intraday trading to $0.96, hitting a weekly high. The stock’s 5-day price performance is -36.84%, and it has moved by -19.33% in 30 days. Based on these gigs, the overall price performance for the year is -86.74%.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -282.28%.

KTTA Dividends

Pasithea Therapeutics Corp is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Also, the Mutual Funds coming in first place with the largest holdings of Pasithea Therapeutics Corp (KTTA) shares are AdvisorShares Trust-AdvisorShares Psychedelics ETF and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . Data provided on Mar 31, 2025 indicates that AdvisorShares Trust-AdvisorShares Psychedelics ETF owns about 53.55 shares. This amounts to just over 1.81 percent of the company’s overall shares, with a $51405.0 market value. The same data shows that the other fund manager holds slightly less at 7.15, or about 0.24% of the stock, which is worth about $6864.0.